%0 Journal Article %T Pilot Study Evaluating the Use of a Commercially Available Oral Nutritional Supplement in the Management of Chronic Kidney Disease in Cats %A Crystal M. Cooley %A Jessica M. Quimby %A Stacie Summers %A Michael R. Lappin %J Open Journal of Veterinary Medicine %P 7-17 %@ 2165-3364 %D 2022 %I Scientific Research Publishing %R 10.4236/ojvm.2021.122002 %X Purpose: To determine if cats with chronic kidney disease (CKD) would willingly consume an oral nutritional supplement formula (NS-CKD) and to assess associated effects on select clinical and biochemical parameters. Methods: Client-owned cats with CKD classified as International Renal Interest Society (IRIS) stage 2 (n = 7), IRIS stage 3 (n = 12), or IRIS stage 4 (1 cat) were classified by the owners as having normal or variable appetites. The cats were offered 30 ml NS-CKD for 14 days concurrently with a meal in a separate bowl and the amount of the NS-CKD consumed daily was recorded. Bodyweight, physical examination, and serum biochemical profiles were assessed on Days 0, 7, and 14. Results: Greater than 50% of the NS-CKD was consumed by 14 of 20 (70%) cats and 12 of 20 cats (60%) consumed >80% of the NS-CKD. The total volume of NS-CKD consumed over the course of the study was statistically greater for the cats classified by owners as having normal appetite (P = 0.046). Increases in body weight were noted for 9 of 14 cats (64.3%) that ingested >50% of the NS-CKD and 1 of 6 cats (16.7%), that ingested Ём 50% (p = 0.1409) and the group mean %